Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
or

Eyepoint Pharmaceuticals Inc (EYPT)

Eyepoint Pharmaceuticals Inc (EYPT)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
5.96 +0.05 (+0.85%) 02/25/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 5.96 unch (unch) 16:02 ET
Quote Overview for Tue, Feb 25th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
5.79
Day High
6.14
Open 5.89
Previous Close 5.91 5.91
Volume 782,100 782,100
Avg Vol 919,435 919,435
Stochastic %K 5.08% 5.08%
Weighted Alpha -72.57 -72.57
5-Day Change -0.58 (-8.87%) -0.58 (-8.87%)
52-Week Range 5.79 - 29.31 5.79 - 29.31
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 403,363
  • Shares Outstanding, K 68,251
  • Annual Sales, $ 46,020 K
  • Annual Income, $ -70,800 K
  • EBIT $ -117 M
  • EBITDA $ -117 M
  • 60-Month Beta 1.51
  • Price/Sales 6.61
  • Price/Cash Flow N/A
  • Price/Book 1.50

Options Overview Details

View History
  • Implied Volatility 100.51% ( -9.75%)
  • Historical Volatility 84.26%
  • IV Percentile 73%
  • IV Rank 52.65%
  • IV High 175.08% on 04/18/24
  • IV Low 17.61% on 07/18/24
  • Put/Call Vol Ratio 27.45
  • Today's Volume 313
  • Volume Avg (30-Day) 328
  • Put/Call OI Ratio 0.57
  • Today's Open Interest 7,586
  • Open Int (30-Day) 8,855

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.41
  • Number of Estimates 3
  • High Estimate -0.31
  • Low Estimate -0.53
  • Prior Year -0.33
  • Growth Rate Est. (year over year) -24.24%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.79 +2.94%
on 02/25/25
Period Open: 8.53
8.68 -31.34%
on 02/05/25
-2.57 (-30.13%)
since 01/24/25
3-Month
5.79 +2.94%
on 02/25/25
Period Open: 9.23
9.50 -37.26%
on 11/26/24
-3.27 (-35.43%)
since 11/25/24
52-Week
5.79 +2.94%
on 02/25/25
Period Open: 26.55
29.31 -79.67%
on 02/27/24
-20.58 (-77.55%)
since 02/23/24

Most Recent Stories

More News
EyePoint to Present Corporate Update at TD Cowen 45th Annual Health Care Conference

EYPT : 5.96 (+0.85%)
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

EYPT : 5.96 (+0.85%)
EyePoint Announces Positive Six-Month Results for the Phase 2 VERONA Clinical Trial of DURAVYUâ„¢ for Diabetic Macular Edema Meeting Primary and Secondary Endpoints

EYPT : 5.96 (+0.85%)
EyePoint to Present at Guggenheim SMID Cap Biotech Conference

EYPT : 5.96 (+0.85%)
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

EYPT : 5.96 (+0.85%)
EyePoint Provides Company Update and Anticipated Development Milestones for 2025

EYPT : 5.96 (+0.85%)
EyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.D., FASRS to Board of Directors

EYPT : 5.96 (+0.85%)
EyePoint to Present at the 43rd Annual J.P. Morgan Healthcare Conference

EYPT : 5.96 (+0.85%)
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

EYPT : 5.96 (+0.85%)
EyePoint Pharmaceuticals Doses First Patient in Phase 3 LUCIA Trial for DURAVYU in Wet AMD

EyePoint Pharmaceuticals initiates LUCIA trial for DURAVYU, evaluating efficacy in wet AMD with data expected in 2026.Quiver AI SummaryEyePoint Pharmaceuticals announced that the first patient has been...

EYPT : 5.96 (+0.85%)

Business Summary

EyePoint Pharmaceuticals Inc. operates as a biopharmaceutical company. It engaged in the development of drug devices to treat debilitating diseases of the eye disorders and other chronic conditions. The company's product candidate consists of DEXYCU(TM). EyePoint Pharmaceuticals Inc., formerly known...

See More

Key Turning Points

3rd Resistance Point 6.49
2nd Resistance Point 6.31
1st Resistance Point 6.14
Last Price 5.96
1st Support Level 5.79
2nd Support Level 5.61
3rd Support Level 5.44

See More

52-Week High 29.31
Fibonacci 61.8% 20.33
Fibonacci 50% 17.55
Fibonacci 38.2% 14.77
Last Price 5.96
52-Week Low 5.79

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

Mastering Fibonacci: The Hidden Order in Market Movements